Efficacy of FLAG Regimen for the Treatment of Patients With AML
NCT ID: NCT03600558
Last Updated: 2020-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2018-11-21
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
NCT04375683
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
NCT00559221
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
NCT02926586
Azacytidine Plus FLAG for Relapsed or Refractory AML
NCT02275663
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
NCT02024308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* De novo or secondary leukemia.
* Treated with FLAG regimen
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ZhongHong Shao
head of department of Hematology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zonghong Shao, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Handong
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.